Role of novel targeted agents in the treatment of metastatic colorectal cancer
作者： Dragan DAMIANOVICH , Niall C TEBBUTT
DOI: 10.1111/J.1743-7563.2006.00081.X
关键词: Oncology 、 Colorectal cancer 、 Cetuximab 、 Irinotecan 、 Chemotherapy 、 Epidermal growth factor receptor 、 Internal medicine 、 Bevacizumab 、 Oxaliplatin 、 Medicine 、 Vascular endothelial growth factor
摘要: Modern chemotherapy regimens, combining bolus or infused schedules of 5-fluorouracil (5-FU) with irinotecan oxaliplatin, have significantly improved the treatment outcomes patients metastatic colorectal cancer (CRC). The addition novel targeted agents to has potential increase median survival CRC beyond 2 years. Bevacizumab, a monoclonal antibody (mAb) vascular endothelial growth factor, an established role in first-line combination either 5-FU/leucovorin irinotecan/5-FU/leucovorin while cetuximab, mAb epidermal factor receptor, is more suitable for refractory CRC. use bevacizumab later stages disease and cetuximab chemotherapy-naive as well concurrent both still under investigation. landmark studies leading approval these associated toxicity profiles detailed recommendations are discussed this review.
sci-hub.se 参考文章(54)
M. G. Zampino, K. Lorizzo, C. Massacesi, A. Rizzi, S. Crispino, S. Boselli, G. Pelosi, L. Zorzino, N. Fazio, F. de Braud, First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer Journal of Clinical Oncology. ,vol. 23, pp. 3659- 3659 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3659
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
K. Margolin, M. S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, J. Breed, Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Journal of Clinical Oncology. ,vol. 19, pp. 851- 856 ,(2001) , 10.1200/JCO.2001.19.3.851
R. S. Kerbel, Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? Science. ,vol. 312, pp. 1171- 1175 ,(2006) , 10.1126/SCIENCE.1125950
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
Andrew J. Dannenberg, Scott M. Lippman, Jason R. Mann, Kotha Subbaramaiah, Raymond N. DuBois, Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention Journal of Clinical Oncology. ,vol. 23, pp. 254- 266 ,(2005) , 10.1200/JCO.2005.09.112
Robert E. Frank, Theodore J. Saclarides, Sue Leurgans, Nicholas J. Speziale, Elizabeth A. Drab, David B. Rubin, Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Annals of Surgery. ,vol. 222, pp. 695- 699 ,(1995) , 10.1097/00000658-199512000-00002
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
R. K. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science. ,vol. 307, pp. 58- 62 ,(2005) , 10.1126/SCIENCE.1104819